speb/financial-data huggingface dataset:
BIO.AX income_statement (annual, 2022-06-30) — Tax Effect Of Unusual Items: 0.00
BIO.AX income_statement (annual, 2022-06-30) — Tax Provision: 0.00
BIO.AX income_statement (annual, 2022-06-30) — Tax Rate For Calcs: 0.00
BIO.AX cash_flow (annual, 2022-06-30) — Taxes Refund Paid Direct: 223275.00
BIO.AX balance_sheet (annual, 2022-06-30) — Total Assets: 9308085.00
BIO.AX balance_sheet (annual, 2022-06-30) — Total Capitalization: 6525047.00
BIO.AX balance_sheet (annual, 2022-06-30) — Total Debt: 467048.00
BIO.AX balance_sheet (annual, 2022-06-30) — Total Equity Gross Minority Interest: 6525047.00
BIO.AX balance_sheet (annual, 2022-06-30) — Total Liabilities Net Minority Interest: 1595541.00
BIO.AX balance_sheet (annual, 2022-06-30) — Total Non Current Assets: 494632.00
BIO.AX balance_sheet (annual, 2022-06-30) — Total Non Current Liabilities Net Minority Interest: 375348.00
BIO.AX income_statement (annual, 2022-06-30) — Total Other Finance Cost: 13526.00
BIO.AX balance_sheet (annual, 2022-06-30) — Working Capital: 7593260.00
BIO.AX income_statement (annual, 2023-06-30) — +Operating Expense: 7629903.00
BIO.AX income_statement (annual, 2023-06-30) — +Total Revenue: 7235611.00
BIO.AX balance_sheet (annual, 2023-06-30) — Accounts Payable: 2274371.00
BIO.AX balance_sheet (annual, 2023-06-30) — Accounts Receivable: 1443044.00
BIO.AX balance_sheet (annual, 2023-06-30) — Accumulated Depreciation: -277565.00
BIO.AX income_statement (annual, 2023-06-30) — Basic Average Shares: 200764764.00
BIO.AX income_statement (annual, 2023-06-30) — Basic EPS: -0.02
BIO.AX cash_flow (annual, 2023-06-30) — Beginning Cash Position: 5493394.00
BIO.AX cash_flow (annual, 2023-06-30) — Capital Expenditure: -400939.00
BIO.AX balance_sheet (annual, 2023-06-30) — Capital Lease Obligations: 375349.00
BIO.AX balance_sheet (annual, 2023-06-30) — Capital Stock: 20764055.00
BIO.AX balance_sheet (annual, 2023-06-30) — Cash And Cash Equivalents: 2260764.00
BIO.AX balance_sheet (annual, 2023-06-30) — Cash Cash Equivalents And Short Term Investments: 2260764.00
BIO.AX balance_sheet (annual, 2023-06-30) — Cash Financial: 2260764.00
BIO.AX cash_flow (annual, 2023-06-30) — Cash Flow From Continuing Financing Activities: 665214.00
BIO.AX cash_flow (annual, 2023-06-30) — Cash Flow From Continuing Investing Activities: -400939.00
BIO.AX cash_flow (annual, 2023-06-30) — Cash Flowsfromusedin Operating Activities Direct: -3496905.00
BIO.AX cash_flow (annual, 2023-06-30) — Changes In Cash: -3232630.00
BIO.AX cash_flow (annual, 2023-06-30) — Classesof Cash Payments: -10473365.00
BIO.AX cash_flow (annual, 2023-06-30) — Classesof Cash Receiptsfrom Operating Activities: 6958054.00
BIO.AX balance_sheet (annual, 2023-06-30) — Common Stock: 20764055.00
BIO.AX balance_sheet (annual, 2023-06-30) — Common Stock Equity: 3586265.00
BIO.AX cash_flow (annual, 2023-06-30) — Common Stock Issuance: 500.00
BIO.AX income_statement (annual, 2023-06-30) — Cost Of Revenue: 2960083.00
BIO.AX balance_sheet (annual, 2023-06-30) — Current Assets: 9792338.00
BIO.AX balance_sheet (annual, 2023-06-30) — Current Capital Lease Obligation: 99584.00
BIO.AX balance_sheet (annual, 2023-06-30) — Current Debt: 125018.00
BIO.AX balance_sheet (annual, 2023-06-30) — Current Debt And Capital Lease Obligation: 224602.00
BIO.AX balance_sheet (annual, 2023-06-30) — Current Liabilities: 2986386.00
BIO.AX income_statement (annual, 2023-06-30) — Depreciation Amortization Depletion Income Statement: 220377.00
BIO.AX income_statement (annual, 2023-06-30) — Depreciation And Amortization In Income Statement: 220377.00
BIO.AX income_statement (annual, 2023-06-30) — Depreciation Income Statement: 220377.00
BIO.AX income_statement (annual, 2023-06-30) — Diluted Average Shares: 200764764.00
BIO.AX income_statement (annual, 2023-06-30) — Diluted EPS: -0.02
BIO.AX income_statement (annual, 2023-06-30) — EBIT: -2984854.00
BIO.AX income_statement (annual, 2023-06-30) — EBITDA: -2764477.00
BIO.AX cash_flow (annual, 2023-06-30) — End Cash Position: 2260764.00
BIO.AX cash_flow (annual, 2023-06-30) — Financing Cash Flow: 665214.00
BIO.AX balance_sheet (annual, 2023-06-30) — Finished Goods: 2971489.00
BIO.AX cash_flow (annual, 2023-06-30) — Free Cash Flow: -3897844.00
BIO.AX balance_sheet (annual, 2023-06-30) — Gains Losses Not Affecting Retained Earnings: 421257.00
BIO.AX income_statement (annual, 2023-06-30) — General And Administrative Expense: 4230310.00
BIO.AX balance_sheet (annual, 2023-06-30) — Gross PPE: 1065823.00
BIO.AX income_statement (annual, 2023-06-30) — Gross Profit: 4275528.00
BIO.AX income_statement (annual, 2023-06-30) — Interest Expense: 93673.00
BIO.AX income_statement (annual, 2023-06-30) — Interest Expense Non Operating: 93673.00
BIO.AX income_statement (annual, 2023-06-30) — Interest Income: 18406.00
BIO.AX income_statement (annual, 2023-06-30) — Interest Income Non Operating: 18406.00
BIO.AX cash_flow (annual, 2023-06-30) — Interest Received Direct: 18406.00
BIO.AX balance_sheet (annual, 2023-06-30) — Inventories Adjustments Allowances: -203345.00
BIO.AX balance_sheet (annual, 2023-06-30) — Inventory: 6042628.00
BIO.AX balance_sheet (annual, 2023-06-30) — Invested Capital: 4356523.00
BIO.AX cash_flow (annual, 2023-06-30) — Investing Cash Flow: -400939.00
BIO.AX cash_flow (annual, 2023-06-30) — Issuance Of Capital Stock: 500.00
BIO.AX cash_flow (annual, 2023-06-30) — Issuance Of Debt: 770258.00
BIO.AX balance_sheet (annual, 2023-06-30) — Leases: 473824.00
BIO.AX balance_sheet (annual, 2023-06-30) — Long Term Capital Lease Obligation: 275765.00
BIO.AX balance_sheet (annual, 2023-06-30) — Long Term Debt: 645240.00
BIO.AX balance_sheet (annual, 2023-06-30) — Long Term Debt And Capital Lease Obligation: 921005.00
BIO.AX cash_flow (annual, 2023-06-30) — Long Term Debt Issuance: 770258.00
BIO.AX cash_flow (annual, 2023-06-30) — Long Term Debt Payments: -13844.00
BIO.AX balance_sheet (annual, 2023-06-30) — Machinery Furniture Equipment: 80040.00
BIO.AX cash_flow (annual, 2023-06-30) — Net Common Stock Issuance: 500.00
BIO.AX income_statement (annual, 2023-06-30) — Net Income: -3078527.00
BIO.AX income_statement (annual, 2023-06-30) — Net Income Common Stockholders: -3078527.00
BIO.AX income_statement (annual, 2023-06-30) — Net Income Continuous Operations: -3078527.00
BIO.AX income_statement (annual, 2023-06-30) — Net Income From Continuing And Discontinued Operation: -3078527.00
BIO.AX income_statement (annual, 2023-06-30) — Net Income From Continuing Operation Net Minority Interest: -3078527.00
BIO.AX income_statement (annual, 2023-06-30) — Net Income Including Noncontrolling Interests: -3078527.00
BIO.AX income_statement (annual, 2023-06-30) — Net Interest Income: -95491.00
BIO.AX cash_flow (annual, 2023-06-30) — Net Issuance Payments Of Debt: 756414.00
BIO.AX cash_flow (annual, 2023-06-30) — Net Long Term Debt Issuance: 756414.00
BIO.AX income_statement (annual, 2023-06-30) — Net Non Operating Interest Income Expense: -95491.00
BIO.AX cash_flow (annual, 2023-06-30) — Net Other Financing Charges: -183400.00
BIO.AX balance_sheet (annual, 2023-06-30) — Net PPE: 788258.00
BIO.AX cash_flow (annual, 2023-06-30) — Net PPE Purchase And Sale: -400939.00
BIO.AX balance_sheet (annual, 2023-06-30) — Net Tangible Assets: 3586265.00
BIO.AX income_statement (annual, 2023-06-30) — Normalized EBITDA: -2764477.00
BIO.AX income_statement (annual, 2023-06-30) — Normalized Income: -3078527.00
BIO.AX income_statement (annual, 2023-06-30) — Operating Income: -3354375.00
BIO.AX income_statement (annual, 2023-06-30) — Operating Revenue: 7235611.00
BIO.AX balance_sheet (annual, 2023-06-30) — Ordinary Shares Number: 201812546.00
BIO.AX cash_flow (annual, 2023-06-30) — Other Cash Paymentsfrom Operating Activities: 20225.00
BIO.AX cash_flow (annual, 2023-06-30) — Other Cash Receiptsfrom Operating Activities: 371339.00
BIO.AX balance_sheet (annual, 2023-06-30) — Other Current Assets: 45902.00
BIO.AX balance_sheet (annual, 2023-06-30) — Other Current Borrowings: 125018.00
BIO.AX balance_sheet (annual, 2023-06-30) — Other Equity Adjustments: 421257.00
BIO.AX income_statement (annual, 2023-06-30) — Other Gand A: 395227.00
BIO.AX income_statement (annual, 2023-06-30) — Other Income Expense: 371339.00
BIO.AX balance_sheet (annual, 2023-06-30) — Other Non Current Liabilities: 65626.00
BIO.AX income_statement (annual, 2023-06-30) — Other Non Operating Income Expenses: 371339.00
BIO.AX income_statement (annual, 2023-06-30) — Other Operating Expenses: 391418.00
BIO.AX balance_sheet (annual, 2023-06-30) — Other Properties: 511959.00
BIO.AX balance_sheet (annual, 2023-06-30) — Payables: 2274371.00
BIO.AX balance_sheet (annual, 2023-06-30) — Payables And Accrued Expenses: 2274371.00
BIO.AX cash_flow (annual, 2023-06-30) — Paymentsto Suppliersfor Goodsand Services: -10493590.00
BIO.AX balance_sheet (annual, 2023-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 487413.00
BIO.AX income_statement (annual, 2023-06-30) — Pretax Income: -3078527.00
BIO.AX cash_flow (annual, 2023-06-30) — Purchase Of PPE: -400939.00
BIO.AX balance_sheet (annual, 2023-06-30) — Raw Materials: 253170.00
BIO.AX cash_flow (annual, 2023-06-30) — Receiptsfrom Customers: 6586715.00
BIO.AX balance_sheet (annual, 2023-06-30) — Receivables: 1443044.00
BIO.AX income_statement (annual, 2023-06-30) — Reconciled Cost Of Revenue: 2960083.00
BIO.AX income_statement (annual, 2023-06-30) — Reconciled Depreciation: 220377.00
BIO.AX income_statement (annual, 2023-06-30) — Rent And Landing Fees: 157568.00
BIO.AX cash_flow (annual, 2023-06-30) — Repayment Of Debt: -13844.00
BIO.AX balance_sheet (annual, 2023-06-30) — Retained Earnings: -17599047.00
BIO.AX income_statement (annual, 2023-06-30) — Salaries And Wages: 3677515.00
BIO.AX income_statement (annual, 2023-06-30) — Selling And Marketing Expense: 2787798.00
BIO.AX income_statement (annual, 2023-06-30) — Selling General And Administration: 7018108.00
BIO.AX balance_sheet (annual, 2023-06-30) — Share Issued: 201812546.00
BIO.AX balance_sheet (annual, 2023-06-30) — Stockholders Equity: 3586265.00
BIO.AX balance_sheet (annual, 2023-06-30) — Tangible Book Value: 3586265.00
BIO.AX income_statement (annual, 2023-06-30) — Tax Effect Of Unusual Items: 0.00
BIO.AX income_statement (annual, 2023-06-30) — Tax Provision: 0.00
BIO.AX income_statement (annual, 2023-06-30) — Tax Rate For Calcs: 0.00
BIO.AX balance_sheet (annual, 2023-06-30) — Total Assets: 10580596.00
BIO.AX balance_sheet (annual, 2023-06-30) — Total Capitalization: 4231505.00
BIO.AX balance_sheet (annual, 2023-06-30) — Total Debt: 1145607.00
BIO.AX balance_sheet (annual, 2023-06-30) — Total Equity Gross Minority Interest: 3586265.00
BIO.AX balance_sheet (annual, 2023-06-30) — Total Liabilities Net Minority Interest: 3973017.00
BIO.AX balance_sheet (annual, 2023-06-30) — Total Non Current Assets: 788258.00
BIO.AX balance_sheet (annual, 2023-06-30) — Total Non Current Liabilities Net Minority Interest: 986631.00
BIO.AX income_statement (annual, 2023-06-30) — Total Other Finance Cost: 20224.00
BIO.AX balance_sheet (annual, 2023-06-30) — Working Capital: 6805952.00
BIO.AX income_statement (annual, 2024-06-30) — +Operating Expense: 9845624.00
BIO.AX income_statement (annual, 2024-06-30) — +Total Revenue: 13008897.00
BIO.AX balance_sheet (annual, 2024-06-30) — Accounts Payable: 2492301.00
BIO.AX balance_sheet (annual, 2024-06-30) — Accounts Receivable: 2870022.00
BIO.AX balance_sheet (annual, 2024-06-30) — Accumulated Depreciation: -558903.00
BIO.AX income_statement (annual, 2024-06-30) — Basic Average Shares: 208040790.00
BIO.AX income_statement (annual, 2024-06-30) — Basic EPS: -0.01
BIO.AX cash_flow (annual, 2024-06-30) — Beginning Cash Position: 2260764.00
BIO.AX cash_flow (annual, 2024-06-30) — Capital Expenditure: -21607.00
BIO.AX balance_sheet (annual, 2024-06-30) — Capital Lease Obligations: 275764.00
BIO.AX balance_sheet (annual, 2024-06-30) — Capital Stock: 21727165.00
BIO.AX balance_sheet (annual, 2024-06-30) — Cash And Cash Equivalents: 2868526.00
BIO.AX balance_sheet (annual, 2024-06-30) — Cash Cash Equivalents And Short Term Investments: 2868526.00
BIO.AX balance_sheet (annual, 2024-06-30) — Cash Financial: 2868526.00
BIO.AX cash_flow (annual, 2024-06-30) — Cash Flow From Continuing Financing Activities: 793175.00
BIO.AX cash_flow (annual, 2024-06-30) — Cash Flow From Continuing Investing Activities: -21607.00
BIO.AX cash_flow (annual, 2024-06-30) — Cash Flowsfromusedin Operating Activities Direct: -163806.00
BIO.AX cash_flow (annual, 2024-06-30) — Changes In Cash: 607762.00
BIO.AX cash_flow (annual, 2024-06-30) — Classesof Cash Payments: -13354625.00
BIO.AX cash_flow (annual, 2024-06-30) — Classesof Cash Receiptsfrom Operating Activities: 13142306.00
BIO.AX balance_sheet (annual, 2024-06-30) — Common Stock: 21727165.00
BIO.AX balance_sheet (annual, 2024-06-30) — Common Stock Equity: 2903528.00
BIO.AX cash_flow (annual, 2024-06-30) — Common Stock Issuance: 642421.00
BIO.AX income_statement (annual, 2024-06-30) — Cost Of Revenue: 5097676.00
BIO.AX balance_sheet (annual, 2024-06-30) — Current Assets: 7708486.00
BIO.AX balance_sheet (annual, 2024-06-30) — Current Capital Lease Obligation: 107952.00
BIO.AX balance_sheet (annual, 2024-06-30) — Current Debt: 1020597.00
BIO.AX balance_sheet (annual, 2024-06-30) — Current Debt And Capital Lease Obligation: 1128549.00
BIO.AX balance_sheet (annual, 2024-06-30) — Current Liabilities: 5143523.00
BIO.AX income_statement (annual, 2024-06-30) — Depreciation Amortization Depletion Income Statement: 241560.00
BIO.AX income_statement (annual, 2024-06-30) — Depreciation And Amortization In Income Statement: 241560.00
BIO.AX income_statement (annual, 2024-06-30) — Depreciation Income Statement: 241560.00
BIO.AX income_statement (annual, 2024-06-30) — Diluted Average Shares: 208040790.00
BIO.AX income_statement (annual, 2024-06-30) — Diluted EPS: -0.01
BIO.AX income_statement (annual, 2024-06-30) — EBIT: -1520577.00
BIO.AX income_statement (annual, 2024-06-30) — EBITDA: -1279017.00
BIO.AX balance_sheet (annual, 2024-06-30) — Employee Benefits: 52570.00
BIO.AX cash_flow (annual, 2024-06-30) — End Cash Position: 2868526.00
BIO.AX cash_flow (annual, 2024-06-30) — Financing Cash Flow: 793175.00
BIO.AX balance_sheet (annual, 2024-06-30) — Finished Goods: 1812308.00
BIO.AX cash_flow (annual, 2024-06-30) — Free Cash Flow: -185413.00
BIO.AX balance_sheet (annual, 2024-06-30) — Gains Losses Not Affecting Retained Earnings: 444212.00
BIO.AX income_statement (annual, 2024-06-30) — General And Administrative Expense: 6310054.00
BIO.AX balance_sheet (annual, 2024-06-30) — Gross PPE: 1127208.00
BIO.AX income_statement (annual, 2024-06-30) — Gross Profit: 7911221.00
BIO.AX income_statement (annual, 2024-06-30) — Interest Expense: 149625.00
BIO.AX income_statement (annual, 2024-06-30) — Interest Expense Non Operating: 149625.00
BIO.AX income_statement (annual, 2024-06-30) — Interest Income: 64212.00
BIO.AX income_statement (annual, 2024-06-30) — Interest Income Non Operating: 64212.00
BIO.AX cash_flow (annual, 2024-06-30) — Interest Paid Direct: -15699.00
BIO.AX cash_flow (annual, 2024-06-30) — Interest Paid Supplemental Data: 15699.00
BIO.AX cash_flow (annual, 2024-06-30) — Interest Received Direct: 64212.00
BIO.AX balance_sheet (annual, 2024-06-30) — Inventories Adjustments Allowances: -306119.00
BIO.AX balance_sheet (annual, 2024-06-30) — Inventory: 1888577.00
BIO.AX balance_sheet (annual, 2024-06-30) — Invested Capital: 3924125.00
BIO.AX cash_flow (annual, 2024-06-30) — Investing Cash Flow: -21607.00
BIO.AX cash_flow (annual, 2024-06-30) — Issuance Of Capital Stock: 642421.00
BIO.AX cash_flow (annual, 2024-06-30) — Issuance Of Debt: 520597.00
BIO.AX balance_sheet (annual, 2024-06-30) — Long Term Capital Lease Obligation: 167812.00
BIO.AX balance_sheet (annual, 2024-06-30) — Long Term Debt And Capital Lease Obligation: 167812.00
BIO.AX cash_flow (annual, 2024-06-30) — Long Term Debt Issuance: 520597.00
BIO.AX cash_flow (annual, 2024-06-30) — Long Term Debt Payments: -270258.00
BIO.AX balance_sheet (annual, 2024-06-30) — Machinery Furniture Equipment: 637019.00
BIO.AX cash_flow (annual, 2024-06-30) — Net Common Stock Issuance: 642421.00
BIO.AX income_statement (annual, 2024-06-30) — Net Income: -1670202.00
BIO.AX income_statement (annual, 2024-06-30) — Net Income Common Stockholders: -1670202.00
BIO.AX income_statement (annual, 2024-06-30) — Net Income Continuous Operations: -1670202.00
BIO.AX income_statement (annual, 2024-06-30) — Net Income From Continuing And Discontinued Operation: -1670202.00
BIO.AX income_statement (annual, 2024-06-30) — Net Income From Continuing Operation Net Minority Interest: -1670202.00
BIO.AX income_statement (annual, 2024-06-30) — Net Income Including Noncontrolling Interests: -1670202.00
BIO.AX income_statement (annual, 2024-06-30) — Net Interest Income: -101112.00
BIO.AX cash_flow (annual, 2024-06-30) — Net Issuance Payments Of Debt: 250339.00
BIO.AX cash_flow (annual, 2024-06-30) — Net Long Term Debt Issuance: 250339.00
BIO.AX income_statement (annual, 2024-06-30) — Net Non Operating Interest Income Expense: -101112.00
BIO.AX cash_flow (annual, 2024-06-30) — Net Other Financing Charges: -199170.00
BIO.AX balance_sheet (annual, 2024-06-30) — Net PPE: 568305.00
BIO.AX cash_flow (annual, 2024-06-30) — Net PPE Purchase And Sale: -21607.00
BIO.AX balance_sheet (annual, 2024-06-30) — Net Tangible Assets: 2903528.00
BIO.AX balance_sheet (annual, 2024-06-30) — Non Current Pension And Other Postretirement Benefit Plans: 52570.00
BIO.AX income_statement (annual, 2024-06-30) — Normalized EBITDA: -1279017.00
BIO.AX income_statement (annual, 2024-06-30) — Normalized Income: -1670202.00
BIO.AX income_statement (annual, 2024-06-30) — Operating Income: -1934403.00
BIO.AX income_statement (annual, 2024-06-30) — Operating Revenue: 13008897.00
BIO.AX balance_sheet (annual, 2024-06-30) — Ordinary Shares Number: 215090901.00
BIO.AX cash_flow (annual, 2024-06-30) — Other Cash Receiptsfrom Operating Activities: 314937.00
BIO.AX balance_sheet (annual, 2024-06-30) — Other Current Assets: 81361.00
BIO.AX balance_sheet (annual, 2024-06-30) — Other Current Borrowings: 1020597.00
BIO.AX balance_sheet (annual, 2024-06-30) — Other Equity Adjustments: 444212.00
BIO.AX income_statement (annual, 2024-06-30) — Other Gand A: 617095.00
BIO.AX income_statement (annual, 2024-06-30) — Other Income Expense: 365313.00
BIO.AX balance_sheet (annual, 2024-06-30) — Other Non Current Liabilities: 9358.00
BIO.AX income_statement (annual, 2024-06-30) — Other Non Operating Income Expenses: 365313.00
BIO.AX income_statement (annual, 2024-06-30) — Other Operating Expenses: 408938.00
BIO.AX balance_sheet (annual, 2024-06-30) — Other Properties: 490189.00
BIO.AX balance_sheet (annual, 2024-06-30) — Payables: 2492301.00
BIO.AX balance_sheet (annual, 2024-06-30) — Payables And Accrued Expenses: 2492301.00
BIO.AX cash_flow (annual, 2024-06-30) — Paymentsto Suppliersfor Goodsand Services: -13354625.00
BIO.AX balance_sheet (annual, 2024-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 1522673.00
BIO.AX income_statement (annual, 2024-06-30) — Pretax Income: -1670202.00
BIO.AX cash_flow (annual, 2024-06-30) — Purchase Of PPE: -21607.00
BIO.AX balance_sheet (annual, 2024-06-30) — Raw Materials: 382388.00
BIO.AX cash_flow (annual, 2024-06-30) — Receiptsfrom Customers: 12790769.00
BIO.AX cash_flow (annual, 2024-06-30) — Receiptsfrom Government Grants: 36600.00
BIO.AX balance_sheet (annual, 2024-06-30) — Receivables: 2870022.00
BIO.AX income_statement (annual, 2024-06-30) — Reconciled Cost Of Revenue: 5097676.00
BIO.AX income_statement (annual, 2024-06-30) — Reconciled Depreciation: 241560.00
BIO.AX income_statement (annual, 2024-06-30) — Rent And Landing Fees: 72846.00
BIO.AX cash_flow (annual, 2024-06-30) — Repayment Of Debt: -270258.00
BIO.AX balance_sheet (annual, 2024-06-30) — Retained Earnings: -19267849.00
BIO.AX income_statement (annual, 2024-06-30) — Salaries And Wages: 5620113.00
BIO.AX income_statement (annual, 2024-06-30) — Selling And Marketing Expense: 2885072.00
BIO.AX income_statement (annual, 2024-06-30) — Selling General And Administration: 9195126.00
BIO.AX balance_sheet (annual, 2024-06-30) — Share Issued: 215090901.00
BIO.AX balance_sheet (annual, 2024-06-30) — Stockholders Equity: 2903528.00
BIO.AX balance_sheet (annual, 2024-06-30) — Tangible Book Value: 2903528.00
BIO.AX income_statement (annual, 2024-06-30) — Tax Effect Of Unusual Items: 0.00
BIO.AX income_statement (annual, 2024-06-30) — Tax Provision: 0.00
BIO.AX income_statement (annual, 2024-06-30) — Tax Rate For Calcs: 0.00
BIO.AX balance_sheet (annual, 2024-06-30) — Total Assets: 8276791.00
BIO.AX balance_sheet (annual, 2024-06-30) — Total Capitalization: 2903528.00
BIO.AX balance_sheet (annual, 2024-06-30) — Total Debt: 1296361.00
BIO.AX balance_sheet (annual, 2024-06-30) — Total Equity Gross Minority Interest: 2903528.00
BIO.AX balance_sheet (annual, 2024-06-30) — Total Liabilities Net Minority Interest: 5373263.00
BIO.AX balance_sheet (annual, 2024-06-30) — Total Non Current Assets: 568305.00
BIO.AX balance_sheet (annual, 2024-06-30) — Total Non Current Liabilities Net Minority Interest: 229740.00
BIO.AX income_statement (annual, 2024-06-30) — Total Other Finance Cost: 15699.00
BIO.AX balance_sheet (annual, 2024-06-30) — Working Capital: 2564963.00
BIO.AX income_statement (annual, 2025-06-30) — Basic Average Shares: 218472578.00
BIO.AX income_statement (annual, 2025-06-30) — Basic EPS: 0.00
BIO.AX income_statement (annual, 2025-06-30) — Diluted Average Shares: 218472578.00
BIO.AX income_statement (annual, 2025-06-30) — Diluted EPS: 0.00
BIO.B balance_sheet (annual, 2021-12-31) — Current Deferred Liabilities: 50852000.00
BIO.B balance_sheet (annual, 2021-12-31) — Current Deferred Revenue: 50852000.00
BIO.B income_statement (annual, 2021-12-31) — Gain On Sale Of Business: 0.00
BIO.B balance_sheet (annual, 2021-12-31) — Income Tax Payable: 10319000.00
BIO.B cash_flow (annual, 2021-12-31) — Issuance Of Debt: 0.00
BIO.B cash_flow (annual, 2021-12-31) — Long Term Debt Issuance: 0.00
BIO.B cash_flow (annual, 2021-12-31) — Net Other Investing Changes: -453440000.00
BIO.B balance_sheet (annual, 2021-12-31) — Other Inventories: 39000.00
BIO.B balance_sheet (annual, 2021-12-31) — Restricted Cash: 5560000.00
BIO.B income_statement (annual, 2022-12-31) — +Operating Expense: 1092200000.00
BIO.B income_statement (annual, 2022-12-31) — +Total Revenue: 2802200000.00
BIO.B balance_sheet (annual, 2022-12-31) — Accounts Payable: 135041000.00
BIO.B balance_sheet (annual, 2022-12-31) — Accounts Receivable: 494645000.00
BIO.B balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -1009400000.00
BIO.B balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 447454000.00
BIO.B balance_sheet (annual, 2022-12-31) — Allowance For Doubtful Accounts Receivable: -15029000.00
BIO.B cash_flow (annual, 2022-12-31) — Asset Impairment Charge: 11900000.00
BIO.B income_statement (annual, 2022-12-31) — Basic Average Shares: 29785000.00
BIO.B income_statement (annual, 2022-12-31) — Basic EPS: -121.79
BIO.B cash_flow (annual, 2022-12-31) — Beginning Cash Position: 471100000.00
BIO.B balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 393600000.00
BIO.B cash_flow (annual, 2022-12-31) — Capital Expenditure: -114300000.00
BIO.B balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 189933000.00
BIO.B balance_sheet (annual, 2022-12-31) — Capital Stock: 3000.00
BIO.B balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 434215000.00
BIO.B balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 1790672000.00
BIO.B cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 973600000.00
BIO.B cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -1207600000.00
BIO.B cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: 194400000.00
BIO.B cash_flow (annual, 2022-12-31) — Change In Account Payable: -94200000.00
BIO.B cash_flow (annual, 2022-12-31) — Change In Income Tax Payable: -1200000.00
BIO.B cash_flow (annual, 2022-12-31) — Change In Inventory: -158800000.00
BIO.B cash_flow (annual, 2022-12-31) — Change In Other Current Assets: -32400000.00
BIO.B cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: 5600000.00
BIO.B cash_flow (annual, 2022-12-31) — Change In Other Working Capital: -1241600000.00
BIO.B cash_flow (annual, 2022-12-31) — Change In Payable: -95400000.00
BIO.B cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: -95400000.00
BIO.B cash_flow (annual, 2022-12-31) — Change In Receivables: -87400000.00
BIO.B cash_flow (annual, 2022-12-31) — Change In Tax Payable: -1200000.00
BIO.B cash_flow (annual, 2022-12-31) — Change In Working Capital: -1610000000.00
BIO.B cash_flow (annual, 2022-12-31) — Changes In Account Receivables: -87400000.00
BIO.B cash_flow (annual, 2022-12-31) — Changes In Cash: -39600000.00
BIO.B balance_sheet (annual, 2022-12-31) — Common Stock: 3000.00
BIO.B balance_sheet (annual, 2022-12-31) — Common Stock Equity: 9615252000.00
BIO.B cash_flow (annual, 2022-12-31) — Common Stock Payments: -215700000.00
BIO.B income_statement (annual, 2022-12-31) — Cost Of Revenue: 1234900000.00
BIO.B balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 194790000.00
BIO.B balance_sheet (annual, 2022-12-31) — Current Assets: 3157976000.00
BIO.B balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 36336000.00
BIO.B balance_sheet (annual, 2022-12-31) — Current Debt: 465000.00
BIO.B balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 36801000.00
BIO.B balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 52211000.00
BIO.B balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 52211000.00
BIO.B balance_sheet (annual, 2022-12-31) — Current Liabilities: 568708000.00
BIO.B cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 137300000.00
BIO.B cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 137300000.00
BIO.B income_statement (annual, 2022-12-31) — Diluted Average Shares: 29785000.00
BIO.B income_statement (annual, 2022-12-31) — Diluted EPS: -121.79
BIO.B income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -3627500000.00
BIO.B income_statement (annual, 2022-12-31) — EBIT: -4666100000.00
BIO.B income_statement (annual, 2022-12-31) — EBITDA: -4528800000.00
BIO.B cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: 3000000.00
BIO.B cash_flow (annual, 2022-12-31) — End Cash Position: 434500000.00
BIO.B cash_flow (annual, 2022-12-31) — Financing Cash Flow: 973600000.00
BIO.B balance_sheet (annual, 2022-12-31) — Finished Goods: 269600000.00
BIO.B cash_flow (annual, 2022-12-31) — Free Cash Flow: 80100000.00
BIO.B cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of Business: -1400000.00
BIO.B income_statement (annual, 2022-12-31) — Gain On Sale Of Business: 1400000.00
BIO.B income_statement (annual, 2022-12-31) — Gain On Sale Of Security: -5191100000.00
BIO.B balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -466822000.00
BIO.B balance_sheet (annual, 2022-12-31) — Goodwill: 406500000.00
BIO.B balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 738600000.00
BIO.B balance_sheet (annual, 2022-12-31) — Gross Accounts Receivable: 509674000.00
BIO.B balance_sheet (annual, 2022-12-31) — Gross PPE: 1688952000.00
BIO.B income_statement (annual, 2022-12-31) — Gross Profit: 1567300000.00
BIO.B balance_sheet (annual, 2022-12-31) — Income Tax Payable: 11929000.00
BIO.B income_statement (annual, 2022-12-31) — Interest Expense: 38100000.00
BIO.B income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 38100000.00
BIO.B income_statement (annual, 2022-12-31) — Interest Income: 58100000.00
BIO.B income_statement (annual, 2022-12-31) — Interest Income Non Operating: 58100000.00
BIO.B balance_sheet (annual, 2022-12-31) — Inventory: 719316000.00
BIO.B balance_sheet (annual, 2022-12-31) — Invested Capital: 10813417000.00
BIO.B cash_flow (annual, 2022-12-31) — Investing Cash Flow: -1207600000.00
BIO.B balance_sheet (annual, 2022-12-31) — Investments And Advances: 8830892000.00
BIO.B cash_flow (annual, 2022-12-31) — Issuance Of Debt: 1186200000.00
BIO.B balance_sheet (annual, 2022-12-31) — Land And Improvements: 27800000.00
BIO.B balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 153597000.00
BIO.B balance_sheet (annual, 2022-12-31) — Long Term Debt: 1197700000.00
BIO.B balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 1351297000.00
BIO.B cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 1186200000.00
BIO.B cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -500000.00
BIO.B cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: -99300000.00
BIO.B cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: -215700000.00
BIO.B balance_sheet (annual, 2022-12-31) — Net Debt: 763950000.00
BIO.B income_statement (annual, 2022-12-31) — Net Income: -3627500000.00
BIO.B income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -3627500000.00
BIO.B income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -3627500000.00
BIO.B income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -3627500000.00
BIO.B income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -3627500000.00
BIO.B cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -3627500000.00
BIO.B income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -3627500000.00
BIO.B cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: -1500000.00
BIO.B income_statement (annual, 2022-12-31) — Net Interest Income: 20000000.00
BIO.B cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -994200000.00
BIO.B cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: 1185700000.00
BIO.B cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: 1185700000.00
BIO.B income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 20000000.00
BIO.B cash_flow (annual, 2022-12-31) — Net Other Financing Charges: -14000000.00
BIO.B balance_sheet (annual, 2022-12-31) — Net PPE: 679552000.00
BIO.B cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -112600000.00
BIO.B balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 8876652000.00
BIO.B balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 1770481000.00
BIO.B balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 1770481000.00
BIO.B income_statement (annual, 2022-12-31) — Normalized EBITDA: 672800000.00
BIO.B income_statement (annual, 2022-12-31) — Normalized Income: 382933600.00
BIO.B cash_flow (annual, 2022-12-31) — Operating Cash Flow: 194400000.00
BIO.B cash_flow (annual, 2022-12-31) — Operating Gains Losses: -1400000.00
BIO.B income_statement (annual, 2022-12-31) — Operating Income: 475100000.00
BIO.B income_statement (annual, 2022-12-31) — Operating Revenue: 2802200000.00
BIO.B balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 29595713.00
BIO.B balance_sheet (annual, 2022-12-31) — Other Current Assets: 23604000.00
BIO.B balance_sheet (annual, 2022-12-31) — Other Current Borrowings: 465000.00
BIO.B balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 169648000.00
BIO.B balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: -466822000.00
BIO.B income_statement (annual, 2022-12-31) — Other Income Expense: -5199300000.00
BIO.B balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 332100000.00
BIO.B balance_sheet (annual, 2022-12-31) — Other Inventories: 16000.00
BIO.B balance_sheet (annual, 2022-12-31) — Other Investments: 8830892000.00
BIO.B cash_flow (annual, 2022-12-31) — Other Non Cash Items: 22100000.00
BIO.B balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 94599000.00
BIO.B balance_sheet (annual, 2022-12-31) — Other Non Current Liabilities: 195928000.00
BIO.B income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: 2300000.00
BIO.B income_statement (annual, 2022-12-31) — Other Operating Expenses: 7500000.00
BIO.B balance_sheet (annual, 2022-12-31) — Other Properties: 1267552000.00
BIO.B balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 1356457000.00
BIO.B balance_sheet (annual, 2022-12-31) — Payables: 167469000.00
BIO.B balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 362259000.00
BIO.B balance_sheet (annual, 2022-12-31) — Preferred Stock: 0.00
BIO.B balance_sheet (annual, 2022-12-31) — Prepaid Assets: 124179000.00
BIO.B income_statement (annual, 2022-12-31) — Pretax Income: -4704200000.00
BIO.B cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 17600000.00
BIO.B balance_sheet (annual, 2022-12-31) — Properties: 0.00
BIO.B income_statement (annual, 2022-12-31) — Provision For Doubtful Accounts: 7500000.00
BIO.B cash_flow (annual, 2022-12-31) — Provisionand Write Offof Assets: 7500000.00
BIO.B cash_flow (annual, 2022-12-31) — Purchase Of Business: -100700000.00
BIO.B cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -1500000.00
BIO.B cash_flow (annual, 2022-12-31) — Purchase Of Investment: -2060200000.00
BIO.B cash_flow (annual, 2022-12-31) — Purchase Of PPE: -112800000.00
BIO.B balance_sheet (annual, 2022-12-31) — Raw Materials: 228800000.00
BIO.B balance_sheet (annual, 2022-12-31) — Receivables: 494645000.00
BIO.B income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 1234900000.00
BIO.B income_statement (annual, 2022-12-31) — Reconciled Depreciation: 137300000.00
BIO.B cash_flow (annual, 2022-12-31) — Repayment Of Debt: -500000.00
BIO.B cash_flow (annual, 2022-12-31) — Repurchase Of Capital Stock: -215700000.00
BIO.B income_statement (annual, 2022-12-31) — Research And Development: 256900000.00
BIO.B balance_sheet (annual, 2022-12-31) — Restricted Cash: 5560000.00
BIO.B balance_sheet (annual, 2022-12-31) — Retained Earnings: 9898203000.00
BIO.B cash_flow (annual, 2022-12-31) — Sale Of Business: 1400000.00
BIO.B cash_flow (annual, 2022-12-31) — Sale Of Investment: 1066000000.00
BIO.B cash_flow (annual, 2022-12-31) — Sale Of PPE: 200000.00
BIO.B income_statement (annual, 2022-12-31) — Selling General And Administration: 827800000.00
BIO.B balance_sheet (annual, 2022-12-31) — Share Issued: 30236205.00
BIO.B income_statement (annual, 2022-12-31) — Special Income Charges: -10500000.00
BIO.B cash_flow (annual, 2022-12-31) — Stock Based Compensation: 60900000.00
BIO.B balance_sheet (annual, 2022-12-31) — Stockholders Equity: 9615252000.00
BIO.B balance_sheet (annual, 2022-12-31) — Tangible Book Value: 8876652000.00
BIO.B income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: -1191166400.00
BIO.B income_statement (annual, 2022-12-31) — Tax Provision: -1076700000.00
BIO.B income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.23
BIO.B balance_sheet (annual, 2022-12-31) — Total Assets: 13501666000.00
BIO.B balance_sheet (annual, 2022-12-31) — Total Capitalization: 10812952000.00
BIO.B balance_sheet (annual, 2022-12-31) — Total Debt: 1388098000.00
BIO.B balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 9615252000.00
BIO.B income_statement (annual, 2022-12-31) — Total Expenses: 2327100000.00
BIO.B balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 3886414000.00
BIO.B balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 10343643000.00
BIO.B balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 3317706000.00
BIO.B income_statement (annual, 2022-12-31) — Total Operating Income As Reported: 482600000.00
BIO.B balance_sheet (annual, 2022-12-31) — Total Tax Payable: 32428000.00
BIO.B income_statement (annual, 2022-12-31) — Total Unusual Items: -5201600000.00
BIO.B income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: -5201600000.00
BIO.B balance_sheet (annual, 2022-12-31) — Treasury Shares Number: 640492.00
BIO.B balance_sheet (annual, 2022-12-31) — Treasury Stock: 263586000.00
BIO.B cash_flow (annual, 2022-12-31) — Unrealized Gain Loss On Investment Securities: 5193600000.00
BIO.B balance_sheet (annual, 2022-12-31) — Work In Process: 220900000.00
BIO.B balance_sheet (annual, 2022-12-31) — Working Capital: 2589268000.00
BIO.B income_statement (annual, 2022-12-31) — Write Off: 11900000.00
BIO.B income_statement (annual, 2023-12-31) — +Operating Expense: 1089100000.00
BIO.B income_statement (annual, 2023-12-31) — +Total Revenue: 2671200000.00
BIO.B balance_sheet (annual, 2023-12-31) — Accounts Payable: 144600000.00
BIO.B balance_sheet (annual, 2023-12-31) — Accounts Receivable: 489000000.00
BIO.B balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -1066700000.00
BIO.B balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 449100000.00
BIO.B balance_sheet (annual, 2023-12-31) — Allowance For Doubtful Accounts Receivable: -14900000.00
BIO.B cash_flow (annual, 2023-12-31) — Asset Impairment Charge: 0.00
BIO.B income_statement (annual, 2023-12-31) — Basic Average Shares: 29209000.00
BIO.B income_statement (annual, 2023-12-31) — Basic EPS: -21.82
BIO.B cash_flow (annual, 2023-12-31) — Beginning Cash Position: 434500000.00
BIO.B balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 419800000.00
BIO.B cash_flow (annual, 2023-12-31) — Capital Expenditure: -156700000.00
BIO.B balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 205900000.00
BIO.B balance_sheet (annual, 2023-12-31) — Capital Stock: 0.00
BIO.B balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 403800000.00
BIO.B balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 1607100000.00
BIO.B cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -425600000.00
BIO.B cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: 20200000.00
BIO.B cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: 374900000.00
BIO.B cash_flow (annual, 2023-12-31) — Change In Account Payable: -51800000.00
BIO.B cash_flow (annual, 2023-12-31) — Change In Income Tax Payable: -21300000.00
BIO.B cash_flow (annual, 2023-12-31) — Change In Inventory: -46300000.00
BIO.B cash_flow (annual, 2023-12-31) — Change In Other Current Assets: 1900000.00
BIO.B cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: -4100000.00
BIO.B cash_flow (annual, 2023-12-31) — Change In Other Working Capital: -322600000.00
BIO.B cash_flow (annual, 2023-12-31) — Change In Payable: -73100000.00
BIO.B cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: -73100000.00
BIO.B cash_flow (annual, 2023-12-31) — Change In Receivables: 11400000.00
BIO.B cash_flow (annual, 2023-12-31) — Change In Tax Payable: -21300000.00
BIO.B cash_flow (annual, 2023-12-31) — Change In Working Capital: -432800000.00
BIO.B cash_flow (annual, 2023-12-31) — Changes In Account Receivables: 11400000.00
BIO.B cash_flow (annual, 2023-12-31) — Changes In Cash: -30500000.00
BIO.B balance_sheet (annual, 2023-12-31) — Common Stock: 0.00
BIO.B balance_sheet (annual, 2023-12-31) — Common Stock Equity: 8741200000.00
BIO.B cash_flow (annual, 2023-12-31) — Common Stock Payments: -428700000.00
BIO.B income_statement (annual, 2023-12-31) — Cost Of Revenue: 1244300000.00
BIO.B balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 139900000.00
BIO.B balance_sheet (annual, 2023-12-31) — Current Assets: 3048300000.00
BIO.B balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 40400000.00
BIO.B balance_sheet (annual, 2023-12-31) — Current Debt: 500000.00
BIO.B balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 40900000.00
BIO.B balance_sheet (annual, 2023-12-31) — Current Liabilities: 522800000.00
BIO.B cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 145900000.00
BIO.B cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 145900000.00
BIO.B income_statement (annual, 2023-12-31) — Diluted Average Shares: 29209000.00
BIO.B income_statement (annual, 2023-12-31) — Diluted EPS: -21.82
BIO.B income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -637300000.00
BIO.B income_statement (annual, 2023-12-31) — EBIT: -800700000.00
BIO.B income_statement (annual, 2023-12-31) — EBITDA: -654800000.00
BIO.B cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: 400000.00
BIO.B cash_flow (annual, 2023-12-31) — End Cash Position: 404400000.00
BIO.B cash_flow (annual, 2023-12-31) — Financing Cash Flow: -425600000.00
BIO.B balance_sheet (annual, 2023-12-31) — Finished Goods: 302900000.00
BIO.B cash_flow (annual, 2023-12-31) — Free Cash Flow: 218200000.00
BIO.B cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of Business: -2500000.00
BIO.B income_statement (annual, 2023-12-31) — Gain On Sale Of Business: 2500000.00
BIO.B income_statement (annual, 2023-12-31) — Gain On Sale Of Security: -1244300000.00
BIO.B balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: -336000000.00
BIO.B balance_sheet (annual, 2023-12-31) — Goodwill: 413600000.00
BIO.B balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 734100000.00
BIO.B balance_sheet (annual, 2023-12-31) — Gross Accounts Receivable: 503900000.00
BIO.B balance_sheet (annual, 2023-12-31) — Gross PPE: 1790400000.00
BIO.B income_statement (annual, 2023-12-31) — Gross Profit: 1426900000.00
BIO.B income_statement (annual, 2023-12-31) — Impairment Of Capital Assets: 0.00
BIO.B income_statement (annual, 2023-12-31) — Interest Expense: 49400000.00
BIO.B income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 49400000.00
BIO.B income_statement (annual, 2023-12-31) — Interest Income: 100900000.00
BIO.B income_statement (annual, 2023-12-31) — Interest Income Non Operating: 100900000.00
BIO.B balance_sheet (annual, 2023-12-31) — Inventory: 780500000.00
BIO.B balance_sheet (annual, 2023-12-31) — Invested Capital: 9940800000.00
BIO.B cash_flow (annual, 2023-12-31) — Investing Cash Flow: 20200000.00
BIO.B balance_sheet (annual, 2023-12-31) — Investments And Advances: 7698100000.00
BIO.B cash_flow (annual, 2023-12-31) — Issuance Of Debt: 0.00
BIO.B balance_sheet (annual, 2023-12-31) — Land And Improvements: 28400000.00
BIO.B balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 165500000.00
BIO.B balance_sheet (annual, 2023-12-31) — Long Term Debt: 1199100000.00
BIO.B balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 1364600000.00
BIO.B cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 0.00
BIO.B cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -500000.00
BIO.B cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 2500000.00
BIO.B cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: -428700000.00
BIO.B balance_sheet (annual, 2023-12-31) — Net Debt: 795800000.00
BIO.B income_statement (annual, 2023-12-31) — Net Income: -637300000.00
BIO.B income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -637300000.00
BIO.B income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -637300000.00
BIO.B income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -637300000.00
BIO.B income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -637300000.00
BIO.B cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -637300000.00
BIO.B income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -637300000.00
BIO.B cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: 0.00
BIO.B income_statement (annual, 2023-12-31) — Net Interest Income: 51500000.00
BIO.B cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 174200000.00
BIO.B cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -500000.00
BIO.B cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -500000.00
BIO.B income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 51500000.00
BIO.B cash_flow (annual, 2023-12-31) — Net Other Financing Charges: -14900000.00
BIO.B balance_sheet (annual, 2023-12-31) — Net PPE: 723700000.00
BIO.B cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -156500000.00
BIO.B balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 8007100000.00
BIO.B balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 1475500000.00
BIO.B balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 1475500000.00
BIO.B income_statement (annual, 2023-12-31) — Normalized EBITDA: 587000000.00
BIO.B income_statement (annual, 2023-12-31) — Normalized Income: 294050000.00
BIO.B cash_flow (annual, 2023-12-31) — Operating Cash Flow: 374900000.00
BIO.B cash_flow (annual, 2023-12-31) — Operating Gains Losses: -2500000.00
BIO.B income_statement (annual, 2023-12-31) — Operating Income: 337800000.00
BIO.B income_statement (annual, 2023-12-31) — Operating Revenue: 2671200000.00
BIO.B balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 28518436.00
BIO.B balance_sheet (annual, 2023-12-31) — Other Current Assets: 26100000.00
BIO.B balance_sheet (annual, 2023-12-31) — Other Current Borrowings: 500000.00
BIO.B balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 161600000.00
BIO.B balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: -336000000.00
BIO.B income_statement (annual, 2023-12-31) — Other Income Expense: -1239400000.00
BIO.B balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 320500000.00
BIO.B balance_sheet (annual, 2023-12-31) — Other Inventories: 17000.00
BIO.B balance_sheet (annual, 2023-12-31) — Other Investments: 7698100000.00
BIO.B cash_flow (annual, 2023-12-31) — Other Non Cash Items: -12000000.00
BIO.B balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 94900000.00
BIO.B balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 195000000.00
BIO.B income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 2400000.00
BIO.B balance_sheet (annual, 2023-12-31) — Other Properties: 1342200000.00
BIO.B balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 1203300000.00
BIO.B income_statement (annual, 2023-12-31) — Other Special Charges: -2500000.00
BIO.B balance_sheet (annual, 2023-12-31) — Payables: 180400000.00
BIO.B balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 320300000.00
BIO.B balance_sheet (annual, 2023-12-31) — Preferred Stock: 0.00
BIO.B balance_sheet (annual, 2023-12-31) — Prepaid Assets: 140000000.00
BIO.B income_statement (annual, 2023-12-31) — Pretax Income: -850100000.00
BIO.B cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 18500000.00
BIO.B balance_sheet (annual, 2023-12-31) — Properties: 0.00
BIO.B income_statement (annual, 2023-12-31) — Provision For Doubtful Accounts: 0.00
BIO.B cash_flow (annual, 2023-12-31) — Provisionand Write Offof Assets: 0.00
BIO.B cash_flow (annual, 2023-12-31) — Purchase Of Business: 0.00
BIO.B cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: 0.00
BIO.B cash_flow (annual, 2023-12-31) — Purchase Of Investment: -689000000.00
BIO.B cash_flow (annual, 2023-12-31) — Purchase Of PPE: -156700000.00
BIO.B balance_sheet (annual, 2023-12-31) — Raw Materials: 231600000.00
BIO.B balance_sheet (annual, 2023-12-31) — Receivables: 489000000.00
BIO.B income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 1244300000.00
BIO.B income_statement (annual, 2023-12-31) — Reconciled Depreciation: 145900000.00
BIO.B cash_flow (annual, 2023-12-31) — Repayment Of Debt: -500000.00
BIO.B cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: -428700000.00
BIO.B income_statement (annual, 2023-12-31) — Research And Development: 247400000.00
BIO.B balance_sheet (annual, 2023-12-31) — Restricted Cash: 5600000.00
BIO.B balance_sheet (annual, 2023-12-31) — Retained Earnings: 9260600000.00
BIO.B cash_flow (annual, 2023-12-31) — Sale Of Business: 2500000.00
BIO.B cash_flow (annual, 2023-12-31) — Sale Of Investment: 863200000.00
BIO.B cash_flow (annual, 2023-12-31) — Sale Of PPE: 200000.00
BIO.B income_statement (annual, 2023-12-31) — Selling General And Administration: 841700000.00
BIO.B balance_sheet (annual, 2023-12-31) — Share Issued: 30265874.00
BIO.B income_statement (annual, 2023-12-31) — Special Income Charges: 2500000.00
BIO.B cash_flow (annual, 2023-12-31) — Stock Based Compensation: 61300000.00
BIO.B balance_sheet (annual, 2023-12-31) — Stockholders Equity: 8741200000.00